Plain-English translation of NCT06777017 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This research study is looking at whether a special type of ultrasound imaging called elastography can help doctors predict if liver cancer will return after treatment with radiofrequency ablation (a heat-based procedure that destroys tumors). The study will measure the stiffness of the liver and spleen using this imaging technique to see if those measurements can signal a higher risk of cancer coming back.
Right now, doctors don't have a reliable way to predict which patients will have their liver cancer return after radiofrequency ablation treatment. This study hopes to find out if the new imaging approach can identify high-risk patients early, which could help doctors plan better follow-up care or consider additional treatments.
You likely qualify if…
You likely don't qualify if…
As a participant, you will undergo elastography imaging (special ultrasound scans) of your liver and spleen before and after your radiofrequency ablation treatment. The researchers will also collect information from your medical records about blood tests and your health status. You'll be followed over time to see whether your cancer returns and to track your overall health, allowing doctors to determine if the imaging measurements were useful in predicting outcomes.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
Italy
Sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Enrollment target
~50 participants
Started
April 2022
Primary completion
May 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in January 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Rocco Maurizio Zagari, MD
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.